Therapeutic equivalence of inhaled beclomethasone dipropionate with CFC and non-CFC (HFA 134a) propellants both delivered via the Easibreathe™ inhaler for the treatment of paediatric asthma

Respiratory Medicine

Volumn 94, Issue 1, 2000, Pages 57-63

  Farmer, I S ^a   Middle, M ^b,f   Savic, J ^c   Perrin, V L ^d   Herdman, M J ^e  

^a Ashford Surgery   (United Kingdom)

^b Republic of South Africa ^*

^c Mother and Child Health Institute

^d Consultant in Pharmaceutical Medicine ^*

^e Clinical Research Consultant   (United Kingdom)

^f Norton Healthcare Ltd   (United Kingdom)

Author keywords

Beclomethasone; Easibreathe ; HFA propellant; Inhalation; Paediatric asthma

Indexed keywords

BECLOMETASONE DIPROPIONATE; CHLOROFLUOROCARBON; HYDROCORTISONE; PROPELLANT;

ARTICLE; ASTHMA; CANDIDIASIS; CHILDHOOD DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HYDROCORTISONE URINE LEVEL; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD;

EID: 0034004611     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1053/rmed.1999.0678     Document Type: Article

References (11)

1. Command Paper no. 977; Treaty Series 1990 (19); Montreal Protocol. Substances that deplete the ozone layer. Montreal, 16th September 1987.
2. Brogden RN, Finder RM, Sawyer PR, Speight TM, Avery GS. Beclomethasone Dipropionate inhaler: A review of its pharmacology, therapeutic values and adverse events. Drugs 1975; 10: 166-210.
3. Ventresca GP. Clinical Pharmacology of HFA-143a. J Aerosol Med 1995; 8 (Suppl. 1): S35-S39.
4. Harrison LI, Donnell D, Simmons JL, Ekholm BP, Cooper KM, Wyld PJ. Twenty-eight day double-blind safety study of an HFA-134a inhalation aerosol system in healthy subjects. J Pharm Pharmacol 1996; 48: 596600.
5. Harrison LI. Pharmacokinetics of HFA-134a: a preliminary report. Am J Therapeut 1996; 3: 763-765.
6. Dahl R, Ringdal N, Ward SM, Stampone P, Donnell D. Equivalence of asthma control with new CFC-free formulation HFA-134a beclomethasone dipropionate and CFC-beclomethasone dipropionate. Br J Clin Pract 1997; 51: 11-15.
7. Davies RJ, Stampone P, O'Connor BJ. Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chloroflurocarbon beclomethasone dipropionate at approximately half the total dose. Respir Med 1998; 92 (Suppl. A): 23-31.
8. Leach C. Enhanced drug delivery through reformulating MDIs with HFA propellants -drug deposition and its effect on preclinical and clinical programs. Resp Drug Delivery 1996; 5: 133-144.
9. Rogers DF, Ganderton D. Determining equivalence of inhaled medications. Worshop report. Respir Med 1995; 89: 253-261.
10. Boulet LP, Cockroft DW, Toogood J, Lacasse Y, Baskerville J, Hargreave FE. Comparative safety and efficacy of inhaled corticosteroids: Report of a Committee of the Canadian Thoracic Society. Eur Resp J 1998; 11: 1194-1210.
11. Milanowski J, Qualtrough J, Perrin V. Inhaled beclomethasone (BDP) with non-CFC propellant (HFA 134a) is equivalent to BDP-CFC for the treatment of asthma. Respir Med 1999; 93: 245-251.